目的 制备人血清白蛋白(human serum albumin,HSA)修饰的盐酸伊立替康(irinotecan hydrochloride, CPT-11) 聚乳酸-羟基乙酸共聚物纳米粒(HSA/PLGA/CPT-11 NPs),对处方进行优化,对制剂进行质量评价,并初步考察其体外抗肿瘤活性。方法 采用乳化-溶剂蒸发法制备HSA/PLGA/CPT-11 NPs,响应面Box-Behnken Design筛选最优处方,并制成冻干粉末。采用激光粒度仪、透射电镜、傅里叶红外光谱(fourier transform infrared spectrometer,FTIR)考察该制剂冻干粉的理化性质,采用透析法考察其体外释放规律,在低温和常温条件下考察其初步稳定性,通过细胞毒性实验初步考察其体外抗肿瘤活性。结果 按优化条件制备的HSA/PLGA/CPT-11 NPs冻干粉呈球形,分布均匀,平均粒径为(98.73±2.04) nm,多分散系数(polydispersity index, PDI)为(0.257±0.03),Zeta电位为(-18.30±0.14) mV,包封率为(64.61±0.29)%。FTIR结果表明,CPT-11被纳米载体包埋后形成了新的物相。体外释放结果显示HSA/PLGA/CPT-11 NPs在24 h时释药80%。初步稳定性试验结果表明HSA/PLGA/CPT-11 NPs冻干粉在4 ℃和25 ℃条件下放置的60 d内具有良好的稳定性。溶血性实验表明,载体材料安全无毒,制备的HSA/PLGA/CPT-11 NPs 冻干制剂适宜静脉注射给药。细胞学实验表明,与游离的CPT-11原料药相比,HSA/PLGA/CPT-11 NPs对人结肠癌HCT-116细胞具有增强的细胞毒性。结论 采用乳化-溶剂蒸发法制备的HSA/PLGA/CPT-11 NPs粒径较小,分布均匀,包封率高,具有明显的药物缓释作用和增强的细胞毒性。
Abstract
OBJECTIVE To enhance the therapeutic effects in colon cancer, the human serum albumin modified irinotecan hydrochloride PLGA nanoparticles (HSA/PLGA/CPT-11 NPs) were prepared based on the optimized prescription. Then, its pharmaceutical property and anti-tumor activity were evaluated. METHODS The HSA/PLGA/CPT-11 NPs were prepared by emulsification-solvent evaporation method, finally made into freeze-dried powder. The response surface method of Box-Behnken Design was used to optimize the initial prescription. The particle size and distribution were measured by Malvern laser granulometer. Transmission electron microscope (TEM) and Fourier transform infrared spectrometer (FTIR) were used to determine the morphology of nanoparticles and the chemical stability of CPT-11, respectively. The in vitro release behavior was determined by dialysis. The preliminary stability was studied at low temperature and room temperature, respectively. Cytotoxicity assay was employed to evaluate the anti-tumor activity of the prepared NPs. RESULTS The TEM images showed that the optimized freeze-dried HSA/PLGA/CPT-11 NPs were spherical in shape, and exhibited good dispersibility. The average particle size of HSA/PLGA/CPT-11 NPs was 98.73±2.04 nm with a polydispersity index (PDI) of 0.257±0.03, and the zeta potential was -18.30±0.14 mV. The encapsulation efficiency of CPT-11 loaded into HSA/PLGA/CPT-11 NPs was 64.61±0.29%. The results of FTIR showed that CPT-11 was embedded in the nanocarrier and formed a new phase, not a simple physical mixture. The in vitro drug release rate of HSA/PLGA/CPT-11 NPs in 24 h reached 80%. The preliminary stability test demonstrated the good stability of freeze-dried HSA/PLGA/CPT-11 NPs under 4 ℃ and 25 ℃ during 60 days, respectively. The hemolytic test shows that the carrier material is safe and non-toxic, and the prepared HSA / PLGA / CPT-11 NPs freeze-dried preparation is suitable for intravenous injection. The cytotoxicity of HSA/PLGA/CPT-11 NPs on HCT-116 cells (human colon cancer cells) was significantly stronger than that of free irinotecan hydrochloride. CONCLUSION The HSA/PLGA/CPT-11 NPs prepared by emulsification-solvent evaporation method exhibited a relative small and uniform particle size, good dispersibility, high encapsulation efficiency, sustained-drug release behavior, and enhanced cytotoxicity.
关键词
盐酸伊立替康 /
聚乳酸-羟基乙酸共聚物 /
人血清白蛋白 /
纳米粒 /
体外抗肿瘤
{{custom_keyword}} /
Key words
irinotecan hydrochloride /
PLGA /
human serum albumin /
nanoparticles /
anti-tumor in vitro
{{custom_keyword}} /
中图分类号:
R944
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] DENG S Q JIANG F, REN J, et al. New Carrier Materials for Particles Drug Delivery System of Irinotecan Hydrochloride[J]. Chin Pharm J(中国药学杂志), 2018, 53(13):1093-1097.
[2] PERRONE E, LOPEZ S, ZEYBEK B, et al. Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan (SN-38) [J]. Front Oncol, 2020, 10: 118.
[3] YANG W, YANG Z, LIU J, et al. Development of a method to quantify total and free irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) for pharmacokinetic and bio-distribution studies after administration of irinotecan liposomal formulation[J]. Asian J Pharm Sci, 2019, 14(6): 687-697.
[4] LI Z, TAN B, ZHANG Z Q, et al. The effect of liposomes on the lactone ring of irinotecan and the effect of drug release in vitro[J]. Chin Pharm J(中国药学杂志), 2008, 43(13):1003-1007.
[5] WANG X, RAO Z, QIN H, et al. Effect of hesperidin on the pharmacokinetics of CPT-11 and its active metabolite SN-38 by regulating hepatic Mrp2 in rats[J]. Biopharm Drug Dispos, 2016, 37(7): 421-432.
[6] PARK D J, WON J H, CHO A R, et al. Determination of irinotecan and its metabolite SN-38 in rabbit plasma and tumors using a validated method of tandem mass spectrometry coupled with liquid chromatography[J]. J Chromatogr B, 2014, 962: 147-152.
[7] DAVID C A W, OWEN A, LIPTROTT N J, et al. Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches[J]. Nanomedicine, 2016, 11(11): 1447-1464.
[8] ISHIHARA T, KANEKO K, ISHIHARA T, et al. Biodegradable nanoparticles for drug delivery and targeting[J]. J Pharm Sci, 2014, 103(12): 4005-4011.
[9] XU Y, KIM C S, SAYLOR D M, et al. Polymer degradation and drug delivery in PLGA-based drug–polymer applications: A review of experiments and theories[J]. J Biomed Mater Res B, 2017, 105(6): 1692-1716.
[10] SOPPIMATH K S, AMINABHAVI T M, KULKARNI A R, et al. Biodegradable polymeric nanoparticles as drug delivery devices[J]. J Controlled Release, 2001, 70(1-2): 1-20.
[11] PANYAM J, ZHOU W Z, PRABHA S, et al. Rapid endo-lysosomal escape of poly (DL-lactide-coglycolide) nanoparticles: implications for drug and gene delivery[J]. FASEB J, 2002, 16(10): 1217-1226.
[12] SILVA-ABREU M, CALPENA A C, ESPINA M, et al. Optimization, biopharmaceutical profile and therapeutic efficacy of pioglitazone-loaded PLGA-PEG nanospheres as a novel strategy for ocular inflammatory disorders[J]. Pharm Res, 2018, 35(1): 1-14.
[13] NOBS L, BUCHEGGER F, GURNY R, et al. Poly(lactic acid) nanoparticles labeled with biologically activeNeutravidin for active targeting[J]. Eur J Pharm Biopharm, 2004, 58(3): 483-490.
[14] ZELPHATI O, UYECHI LS, BARRON LG, et al. Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells[J]. BBA Lipids Metab, 1998, 1390(2): 119-133.
[15] KRATZ F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles[J]. J Controlled Release, 2008, 132(3):171-183.
[16] HASHAD R A, ISHAK R A H, GENEIDI A S, et al. Surface functionalization of methotrexate-loaded chitosan nanoparticles with hyaluronic acid/human serum albumin: Comparative characterization and in vitro cytotoxicity[J]. Int J Pharm, 2017, 522(1-2): 128-136.
[17] WANG J Z, BING Y P, LI F, et al. Preparation of bovine serum albumin-modified PLGA nanoparticles loaded with naringenin[J]. Chin Tradit Pat Med(中成药), 2019, 41(11):2566-2571.
[18] JIN W Z, TAN H J, WANG K K, et al. Construction of Matrine Solid Lipid Nanoparticle and Determination of the Entrapment Efficiency[J]. Chin Pharm J(中国药学杂志), 2020, 55(12):1015-1020.
[19] HUANG W Z, CAI Z F, ZHANG Q M. Study on Spectrophometry Determination of Injection hemolysis[J]. Pharm Today(今日药学), 2016, 26(10):713-716,720.
[20] DENG L, LI L, YANG H, et al. Development and optimization of doxorubicin loaded poly (lactic-co-glycolic acid) nanobubbles for drug delivery into HeLa cells[J]. J Nanosci Nanotechnol, 2014, 14(4): 2947-2954.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}